Skip to main content

Table 3 Characteristics of cancer patients treated and pegfilgrastim administration options at oncology centers

From: Health professionals’ preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia

Variable

Participants

n = 60

n

%

Number of patients with breast cancer, NHL, NSCLC and/or colorectal cancer seen in one-month a

150 (50–300)

Percentage of patients with breast cancer, NHL, NSCLC and/or colorectal cancer with pegfilgrastim b

60,3 (25,6)

70 (40–80)

Options for pegfilgrastim administration that have been used by physicians

  

Same day as myelosuppressive chemotherapy, in the clinic, by a HCP

40

66,7

Administered when the patient returns to the clinic, 24 h after myelosuppressive chemotherapy, specifically to receive an injection of pegfilgrastim from a HCP

48

80

Administered when the patient returns to the clinic, 48–72 h after myelosuppressive chemotherapy, specifically to receive an injection of pegfilgrastim from a HCP

25

41,7

Home administration using Neulastim (OBI) that has been attached to the patient’s arm or abdomen in the clinic; approximately 24 h (just over 1 day) after myelosuppressive chemotherapy

47

78,3